MORE►
RA Session II
Signify Bio co-founders, from left: CEO R.A. Session II and Chief Scientific Officer Daniel Siegwart, Ph.D., of UT Southwestern. {Photos: Taysha Gene Therapies/UTSW]
Dallas’ Signify Bio Launches With Oversubscribed $15M Financing, Partnership With UT Southwestern
by Lance Murray | Jun 5, 2025
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Kevin Cummings |
Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Session II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Session II says.
MORE►
